Abstract

Several thousand different types of rare diseases and disorders exist, with more being discovered each day. In recent years, the interest for rare diseases has grown throughout the entire medical community. However, the road to an approved orphan drug is a long and costly one with many challenges on the way including regulatory, financial, sustainability and pricing and reimbursement issues.